<DOC>
	<DOCNO>NCT02018419</DOCNO>
	<brief_summary>This phase I/II study design compare different treatment schedule personalize anti-cancer vaccine protocol combine cryoablation select metastatic lesion intra-tumor immunotherapy . The cryoablation cause tumor release tumor-specific antigen surround environment . The injection bioengineered allogeneic immune cell , AlloStim ( TM ) , lesion design modulate immune response educate immune system kill tumor cell .</brief_summary>
	<brief_title>Increased Frequency AlloStim ( TM ) Dosing Combination With Cryoablation Metastatic Breast Cancer Patients</brief_title>
	<detailed_description>The study assess three different dose schedule . A standard 3 plus 3 study design use . The start dose dose schedule escalate subsequent group patient . The study evaluate safety increase frequency AlloStim ( TM ) dose anti-tumor effect new propose dose frequency schedule .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Women w/ histologically/cytologically confirm breast carcinoma 2 . Documented progressive metastatic disease amenable curative surgery/radiotherapy 3 . Age ≥18 ≤70 year 4 . Prior treatment include capecitabine anthracycline taxane drug resistant taxane therapy 1 . ER+ patient : minimum cumulative dose anthracycline ( ≥ 180 mg/m² doxorubicin ≥ 300 mg/m² epirubicin ) resistance anthracycline , capecitabine antihormonal therapy 2 . Resistance define tumor progression receive treatment progression within 4 month last dose metastatic setting , recurrence within 12 month neoadjuvant/adjuvant set 5 . Postmenopausal ER+ and/or PR+ must receive least 2 line prior antiestrogen therapy , include aromatase inhibitor 6 . Her2+ patient : least 1 Her2+ target regimen contain trastuzumab alone pertuzumab/lapatinib . Trastuzumab/pertuzumab must discontinue least 4 week treatment 7 . Prior radiation therapy complete &gt; 4 week treatment 8 . Measurable disease accord revise RECIST v.1.1 guideline least 1 lesion deem safely accessible serial biopsy 9 . ECOG &lt; 2 10 . Adequate hematological function 1 . Absolute granulocyte count ≥ 1,500/mm3 2 . Platelet count ≥ 100,000/mm3 3 . PT/INR ≤ 1.5 4 . INR correctable ≤ 1.5 PT/PTT correctable normal limit . Patients receive anticoagulation treatment agent warfarin/heparin may participate . For patient warfarin , INR monitor weekly prior intervention assure INR stable . Heparin/warfarin must withhold biopsy 5 . Hemoglobin ≥ 9 g/dL ( may correct transfusion ) 11 . Adequate organ function 1 . Creatinine ≤ 1.5 mg/dL 2 . Total bilirubin ≤ 1.5 time ULN 3 . Alkaline phosphatase≤2.5 time ULN ( ≤5 time normal liver involvement ) 4 . Aspartate aminotransferase ( AST/SGOT ) ≤ 5.0 time ULN 5 . Alanine aminotransferase ( ALT/SGPT ) ≤ 5.0 time ULN 12 . EKG without clinically relevant abnormality 13 . Premenopausal child bear potential subject must use adequate contraception 14 . Informed consent native language subject 1 . Peritoneal carcinomatosis 2 . Moderatelarge ascites accumulation requiring/likely require paracentesis 3 . Clinical/radiological evidence brain metastasis/leptomeningeal involvement 4 . Pulmonary lymphangitis/symptomatic pleural effusion ( grade ≥ 2 ) result pulmonary dysfunction require active treatment 5 . History 2nd primary malignancy , except : bilateral breast carcinoma , situ carcinoma cervix , adequately treat nonmelanomatous carcinoma skin , malignancy treat least 5 year evidence recurrence 6 . &gt; 3 prior chemotherapy regimens metastatic disease 7 . History severe hypersensitivity monoclonal antibody drugs/any contraindication study drug 8 . Pregnant breast feed 9 . Any serious , concurrent uncontrolled medical disorder 10 . Prior hepatectomy , liver chemoembolization , liver cryoablation/ radiofrequency ablate 11 . Symptomatic pulmonary disease 12 . Bevacizumab ( Avastin® ) within 3 week accrual 13 . Prior allogeneic bone marrow/stem cell solid organ transplant 14 . Chronic use ( &gt; 2 week ) great physiologic dos corticosteroid agent ( dose equivalent &gt; 10 mg/day prednisone ) within 30 day first day study treatment . Topical inhale corticosteroid permit 15 . Concomitant active autoimmune disease 16 . Prior experimental therapy/cancer vaccine treatment 17 . Current immunosuppressive therapy , include : cyclosporine , antithymocyte globulin , tacrolimus within 1 month study entry 18 . History blood transfusion reaction 19 . Known allergy bovine product 20 . Know allergy murine product 21 . Progressive viral/bacterial infection . All infection must resolve patient must remain afebrile 7days without antibiotic prior enrollment 22 . Cardiac disease symptomatic nature cardiac ejection fraction &lt; 45 % 23 . History HIV positivity AIDS 24 . Psychiatric/addictive disorder condition , opinion investigator , would preclude study participation 25 . Concurrent medication know interfere platelet function coagulation ( e.g. , aspirin , ibuprofen , clopidogrel , warfarin ) unless discontinue appropriate time period base drug halflife know activity ( e.g. , aspirin 7 day ) prior cryoablation procedure 26 . Use low molecular weight heparin preparation unless discontinue 8 hour prior cryoablation</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>